Anti-SOX2 antibody [EPR3131],Abcam,AB92494

Anti-SOX2 antibody [EPR3131] (ab92494) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IHC - Wmt, IHC-P, WB and sELISA. Anti-SOX2 antibody [EPR3131] (ab92494) was first used in a scientific publication in 2011 and has been cited over 236 times in peer reviewed journals. It's performance in Western Blot in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-SOX2 antibody [EPR3131] (ab92494) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-SOX2 antibody [EPR3131] (ab92494) has 23 independent reviews from customers. Anti-SOX2 antibody [EPR3131] (ab92494) specifically detects SOX2 (UniProt ID: P48431; Molecular weight: 35kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR3131 - ab215970 . Antibody clone EPR3131 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, Alexa Fluor ® 594, Alexa Fluor ® 568, Alexa Fluor ® 555 ( ab195358 , ab196637 , ab302657 , ab302801 , ab305364 ). SOX2 is a crucial transcription factor in neuro research, particularly for its role in maintaining neural stem cell pluripotency and regulating neural development. It is essential for the proliferation and differentiation of neural progenitor cells, influencing brain development and repair. Researchers use SOX2 to study neural stem cell behaviour, neurogenesis and the mechanisms underlying neurodevelopmental disorders, making it vital for understanding brain development and potential regenerative therapies Additionally, SOX2 plays a significant role in gliomas, particularly glioblastoma (GBM), the most aggressive form of brain cancer. Elevated SOX2 levels are associated with poor prognosis and tumor progression in glioblastoma patients. Targeting SOX2 expression and function is being explored as a potential therapeutic strategy to combat gliomas and improve patient outcomes. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .